Published in J Gen Virol on March 01, 1986
Antibody protects against lethal infection with the neurally spreading reovirus type 3 (Dearing). J Virol (1988) 3.84
Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol (2007) 2.89
Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol (1986) 2.26
Immunization of mice with recombinant vaccinia virus expressing authentic dengue virus nonstructural protein NS1 protects against lethal dengue virus encephalitis. J Virol (1990) 2.05
The development of therapeutic antibodies that neutralize homologous and heterologous genotypes of dengue virus type 1. PLoS Pathog (2010) 2.03
Antibodies against West Nile Virus nonstructural protein NS1 prevent lethal infection through Fc gamma receptor-dependent and -independent mechanisms. J Virol (2006) 1.91
Complement activation is required for induction of a protective antibody response against West Nile virus infection. J Virol (2005) 1.75
Genetic analysis of the yellow fever virus NS1 protein: identification of a temperature-sensitive mutation which blocks RNA accumulation. J Virol (1997) 1.65
Binding of flavivirus nonstructural protein NS1 to C4b binding protein modulates complement activation. J Immunol (2011) 1.45
Additive effects characterize the interaction of antibodies involved in neutralization of the primary dualtropic human immunodeficiency virus type 1 isolate 89.6. J Virol (2001) 1.35
High-level expression of the tick-borne encephalitis virus NS1 protein by using an adenovirus-based vector: protection elicited in a murine model. J Virol (1992) 1.18
Immune correlates of protection against yellow fever determined by passive immunization and challenge in the hamster model. Vaccine (2011) 1.15
Protective efficacy of nonneutralizing monoclonal antibodies in acute infection with murine leukemia virus. J Virol (1995) 1.14
Virus-specific cytolytic antibodies to nonstructural protein 1 of Japanese encephalitis virus effect reduction of virus output from infected cells. J Virol (2009) 1.10
Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccines. Clin Vaccine Immunol (2014) 1.06
Characterization of a siberian virus isolated from a patient with progressive chronic tick-borne encephalitis. J Virol (2003) 1.02
Pre- and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J Virol (1997) 0.98
A short N-terminal peptide motif on flavivirus nonstructural protein NS1 modulates cellular targeting and immune recognition. J Virol (2010) 0.96
CD8+ T cells complement antibodies in protecting against yellow fever virus. J Immunol (2014) 0.87
Issues related to recent dengue vaccine development. Trop Med Health (2011) 0.86
Immunization with nonstructural proteins promotes functional recovery of alphavirus-infected neurons. J Virol (1997) 0.83
Flavivirus nonstructural protein NS1: complementary surprises. Proc Natl Acad Sci U S A (2006) 0.80
How to approach and treat viral infections in ICU patients. BMC Infect Dis (2014) 0.77
Herpes simplex virus 2 (HSV-2) infected cell proteins are among the most dominant antigens of a live-attenuated HSV-2 vaccine. PLoS One (2015) 0.76
A humanized monoclonal antibody neutralizes yellow fever virus strain 17D-204 in vitro but does not protect a mouse model from disease. Antiviral Res (2016) 0.75
Biomarkers in Japanese encephalitis: a review. Biomed Res Int (2013) 0.75
Population dynamics of flaviviruses revealed by molecular phylogenies. Proc Natl Acad Sci U S A (1996) 3.69
High-level resistance to (-) enantiomeric 2'-deoxy-3'-thiacytidine in vitro is due to one amino acid substitution in the catalytic site of human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother (1993) 3.57
The separated enantiomers of 2'-deoxy-3'-thiacytidine (BCH 189) both inhibit human immunodeficiency virus replication in vitro. Antimicrob Agents Chemother (1992) 3.22
Evolutionary relationships of endemic/epidemic and sylvatic dengue viruses. J Virol (2000) 3.21
The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2',3'-dideoxyinosine and 2',3'-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2',3'-dideoxy-3'-thiacytidine. Antimicrob Agents Chemother (1993) 3.00
Biophysical characterization and vector-specific antagonist activity of domain III of the tick-borne flavivirus envelope protein. J Virol (2001) 2.59
(-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro. Antimicrob Agents Chemother (1992) 2.58
First cases of autochthonous dengue fever and chikungunya fever in France: from bad dream to reality! Clin Microbiol Infect (2010) 2.53
Tick-borne virus diseases of human interest in Europe. Clin Microbiol Infect (2004) 2.30
Phylogeny of the Simbu serogroup of the genus Bunyavirus. J Gen Virol (2001) 2.30
Tick-borne encephalitis. Antiviral Res (2003) 2.25
Phylogenetic relationships of flaviviruses correlate with their epidemiology, disease association and biogeography. J Gen Virol (2001) 2.19
A prospective comparison of selective and universal electronic fetal monitoring in 34,995 pregnancies. N Engl J Med (1986) 2.15
EQ-5D in patients with dementia: an investigation of inter-rater agreement. Med Care (2001) 2.06
Translation deficiency of the Sabin type 3 poliovirus genome: association with an attenuating mutation C472----U. Virology (1990) 2.03
The relationships between West Nile and Kunjin viruses. Emerg Infect Dis (2001) 2.03
Nucleotide changes responsible for loss of neuroinvasiveness in Japanese encephalitis virus neutralization-resistant mutants. Virology (1991) 1.85
Complete coding sequence of the Alkhurma virus, a tick-borne flavivirus causing severe hemorrhagic fever in humans in Saudi Arabia. Biochem Biophys Res Commun (2001) 1.85
Secondary structure of the 3' untranslated region of flaviviruses: similarities and differences. Nucleic Acids Res (1997) 1.84
Defective interfering viruses and infections of animals. Curr Top Microbiol Immunol (1986) 1.83
Strain-gradient-induced polarization in SrTiO3 single crystals. Phys Rev Lett (2007) 1.77
Monoclonal antibodies to Sindbis virus glycoprotein E1 can neutralize, enhance infectivity, and independently inhibit haemagglutination or haemolysis. J Gen Virol (1982) 1.77
Genetic variation in the 3' non-coding region of dengue viruses. Virology (2001) 1.71
Nucleotide sequences and phylogeny of the nucleocapsid gene of Oropouche virus. J Gen Virol (2000) 1.70
An arbovirus cline across the northern hemisphere. Virology (1995) 1.67
Sustained release of epidermal growth factor accelerates wound repair. Proc Natl Acad Sci U S A (1985) 1.66
Single mutations at many sites within the DNA polymerase locus of herpes simplex viruses can confer hypersensitivity to aphidicolin and resistance to phosphonoacetic acid. J Gen Virol (1984) 1.66
Chimeric yellow fever virus 17D-Japanese encephalitis virus vaccine: dose-response effectiveness and extended safety testing in rhesus monkeys. J Virol (2000) 1.64
Complete sequence of two tick-borne flaviviruses isolated from Siberia and the UK: analysis and significance of the 5' and 3'-UTRs. Virus Res (1997) 1.63
Molecular epidemiology of dengue virus type 3 in Venezuela. J Gen Virol (2003) 1.61
Presence of epidermal-derived thymocyte activating factor/interleukin 1 in normal human stratum corneum. J Clin Invest (1985) 1.61
Development of HIV-1 resistance to (-)2'-deoxy-3'-thiacytidine in patients with AIDS or advanced AIDS-related complex. AIDS (1995) 1.58
Genetic variation in yellow fever virus: duplication in the 3' noncoding region of strains from Africa. Virology (1996) 1.53
Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro. J Virol (2005) 1.53
Examination of the immunological relationships between flaviviruses using yellow fever virus monoclonal antibodies. J Gen Virol (1985) 1.50
Molecular epidemiology of dengue type 2 virus in Venezuela: evidence for in situ virus evolution and recombination. J Gen Virol (2001) 1.48
Phylogenetic and evolutionary relationships among yellow fever virus isolates in Africa. J Virol (2001) 1.47
Nucleotide sequence of a neurovirulent variant of the type 2 oral poliovirus vaccine. J Virol (1989) 1.46
A reevaluation of the higher taxonomy of viruses based on RNA polymerases. J Virol (1996) 1.44
Comparison of the genomes of the wild-type French viscerotropic strain of yellow fever virus with its vaccine derivative French neurotropic vaccine. J Gen Virol (1995) 1.44
Accelerated wound repair, cell proliferation, and collagen accumulation are produced by a cartilage-derived growth factor. J Cell Biol (1985) 1.41
Infectious transcripts of tick-borne encephalitis virus, generated in days by RT-PCR. Virology (1995) 1.32
Understanding of informed consent by demented individuals. Neurology (2003) 1.31
Rapid identification of flaviviruses based on conserved NS5 gene sequences. J Virol Methods (1993) 1.30
Attenuation of Japanese encephalitis virus by selection of its mouse brain membrane receptor preparation escape variants. Virology (1998) 1.30
Nucleotide sequence of the envelope glycoprotein of Negishi virus shows very close homology to louping ill virus. Virology (1992) 1.29
Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14. J Gen Virol (1995) 1.29
Recombinant basic fibroblast growth factor accelerates wound healing. J Surg Res (1988) 1.29
Single amino acid codon changes detected in louping ill virus antibody-resistant mutants with reduced neurovirulence. J Gen Virol (1993) 1.28
Secondary structure of the 3'-untranslated region of yellow fever virus: implications for virulence, attenuation and vaccine development. J Gen Virol (1997) 1.28
Mutation in a 17D-204 vaccine substrain-specific envelope protein epitope alters the pathogenesis of yellow fever virus in mice. Virology (1998) 1.28
Infection patterns in mice of an avirulent and virulent strain of Semliki Forest virus. Br J Exp Pathol (1971) 1.26
The vulnerability of the hippocampus to protective and destructive effects of glucocorticoids in relation to stress. Br J Psychiatry Suppl (1992) 1.24
Analysis of flavivirus envelope proteins reveals variable domains that reflect their antigenicity and may determine their pathogenesis. Virus Res (1995) 1.24
Biological consequences of deletions within the 3'-untranslated region of flaviviruses may be due to rearrangements of RNA secondary structure. Virus Res (1999) 1.22
Virus excretion and mutation by infants following primary vaccination with live oral poliovaccine from two sources. J Med Virol (1990) 1.22
Improved sweat test method for the diagnosis of cystic fibrosis. Arch Dis Child (1984) 1.20
Jatobal virus is a reassortant containing the small RNA of Oropouche virus. Virus Res (2001) 1.20
Phylogeny of TYU, SRE, and CFA virus: different evolutionary rates in the genus Flavivirus. Virology (1995) 1.17
Detection of virus-specific antigen in the nuclei or nucleoli of cells infected with Zika or Langat virus. J Gen Virol (1988) 1.16
Molecular epidemiological studies of veterinary arboviral encephalitides. Vet J (1999) 1.15
Phylogeny of the genus flavivirus using complete coding sequences of arthropod-borne viruses and viruses with no known vector. J Gen Virol (2000) 1.14
Antibody-dependent enhancement of yellow fever and Japanese encephalitis virus neurovirulence. J Gen Virol (1989) 1.14
Passage of Japanese encephalitis virus in HeLa cells results in attenuation of virulence in mice. J Gen Virol (1995) 1.13
HIV protease genotype and viral sensitivity to HIV protease inhibitors following saquinavir therapy. AIDS (1998) 1.13
Recombination in rabbit haemorrhagic disease virus: possible impact on evolution and epidemiology. Virology (2008) 1.13
Antibody-mediated early death in vivo after infection with yellow fever virus. J Gen Virol (1986) 1.13
Comparison of nucleotide and deduced amino acid sequence of the 5' non-coding region and structural protein genes of the wild-type Japanese encephalitis virus strain SA14 and its attenuated vaccine derivatives. J Gen Virol (1994) 1.11
Towards a new generation of flavivirus vaccines. Vaccine (1994) 1.10
Characterization of envelope glycoprotein gp41 genotype and phenotypic susceptibility to enfuvirtide at baseline and on treatment in the phase III clinical trials TORO-1 and TORO-2. AIDS Res Hum Retroviruses (2006) 1.10
Recombinant vaccinia virus/Venezuelan equine encephalitis (VEE) virus protects mice from peripheral VEE virus challenge. J Virol (1988) 1.10
Origin and evolution of 3'UTR of flaviviruses: long direct repeats as a basis for the formation of secondary structures and their significance for virus transmission. Adv Virus Res (2007) 1.09
Elevated stress hormone levels relate to Epstein-Barr virus reactivation in astronauts. Psychosom Med (2001) 1.08
West Nile virus strains differ in mouse neurovirulence and binding to mouse or human brain membrane receptor preparations. Ann N Y Acad Sci (2001) 1.07
Evolution of base composition and codon usage bias in the genus Flavivirus. J Mol Evol (2001) 1.07
Immunization with a portion of rickettsial outer membrane protein A stimulates protective immunity against spotted fever rickettsiosis. Vaccine (2001) 1.07
Antigenic variants of yellow fever virus with an altered neurovirulence phenotype in mice. Virology (1997) 1.07
The virus causing encephalomyelitis in sheep in Spain: a new member of the tick-borne encephalitis group. Res Vet Sci (1995) 1.06
Interaction of yellow fever virus French neurotropic vaccine strain with monkey brain: characterization of monkey brain membrane receptor escape variants. J Virol (2000) 1.06
Studies of the basis of localization of influenza virus in ferret organ cultures. Br J Exp Pathol (1972) 1.05
Identification of naturally occurring monoclonal antibody escape variants of louping ill virus. J Gen Virol (1994) 1.05
Benign circulation of rabbit haemorrhagic disease virus on Lambay Island, Eire. Virology (2006) 1.04
Rapid subgroup identification of the flaviviruses using degenerate primer E-gene RT-PCR and site specific restriction enzyme analysis. J Virol Methods (2005) 1.04
Molecular and biological changes associated with HeLa cell attenuation of wild-type yellow fever virus. Virology (1999) 1.03
Prospects for a virus non-structural protein as a subunit vaccine. Vaccine (1988) 1.03
Nucleotide and deduced amino acid sequence of the structural protein genes of Japanese encephalitis viruses from different geographical locations. J Gen Virol (1995) 1.03
The production of a temperature-sensitive persistent measles virus infection. J Gen Virol (1975) 1.02
Characterization of a siberian virus isolated from a patient with progressive chronic tick-borne encephalitis. J Virol (2003) 1.02
Analysis of the structural protein gene sequence shows Kyasanur Forest disease virus as a distinct member in the tick-borne encephalitis virus serocomplex. J Gen Virol (1994) 1.02
Monoclonal antibodies identify the NS5 yellow fever virus non-structural protein in the nuclei of infected cells. J Gen Virol (1992) 1.02
Molecular epidemiology of Rabbit haemorrhagic disease virus. J Gen Virol (2002) 1.01
Molecular differences between wild-type Japanese encephalitis virus strains of high and low mouse neuroinvasiveness. J Gen Virol (1996) 1.01
Anti-human immunodeficiency virus and anti-hepatitis-B virus activities and toxicities of the enantiomers of 2'-deoxy-3'-oxa-4'-thiocytidine and their 5-fluoro analogues in vitro. J Med Chem (1995) 1.01